ZOLESTA

Zoledronic acid, or CGP 42'446, 8 is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid.

Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget's disease of bone. 14, 15, 16 Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted

FDA approval on 20 August 2001.

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. 14, 15, 16 Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis. 14, 15,

Zoledronic acid is a third generation, nitrogen containing bisphosphonate that inhibits osteoclast function and prevents bone resorption.

The therapeutic window is wide as patients are unlikely to suffer severe effects from overdoses and the duration of action is long. 14, 15, 16 Patients should be counselled regarding the risk of electrolyte deficiencies, renal impairment, osteonecrosis of the jaw, atypical femoral fractures, bronchoconstriction, hepatic impairment, hypocalcemia, and embryo-fetal toxicity. 14, 15, 16.

Geranylgeranyl pyrophosphate synthase Inhibitor Hydroxylapatite

Antagonist Binder Farnesyl pyrophosphate synthase Inhibitor.

A 4 mg intravenous dose reaches a C max of 370±78.5ng/mL, with a T max of 0.317±0.014h, and an AUC of 788±181ng*h/mL.

A 5 mg intravenous dose reaches a C max of 471±76.1ng/mL, with a T max of 0.368±0.005h, and an AUC of 917±226ng*h/mL.

Zoledronic acid is not metabolized in vivio. 14, 15, 16.

Zoledronic acid is 39 ± 16% eliminated in the urine as the unmetabolized parent drug. 14, 15, 16.

Zoledronic acid has a terminal elimination half life of 146 hours. 14, 15, 16.

Zoledronic acid has a renal clearance of 3.7 ± 2.0 L/h. 14, 15, 16.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Patients experiencing an overdose may present with renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. 14, 15, 16 Overdose should be managed through intravenous administration of the insufficient ions. 14, 15, 16.

For external use only.

Do not use more than one acne product at a time.

After area is wet with

Blemfree™ Cleansing Wash Concentrate has foamed, tap Blemfree™ Cleansing Spheres with fingertips and massage in small circles for 60 seconds.

Proceed to rinse step.